Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

Here, we discuss a handful of the new treatment options in development

By: SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

Optometric Management July 16, 2025 Vol 60(6), Issue July/August 2025 Page(s): 12

5 Key Takeaways

1

Reproxalap is a reactive aldehyde species modulator in phase 3 trials, targeting inflammation in dry eye disease and allergies.
2

AZR-MD-001 is an ophthalmic ointment in phase 3 trials aimed at improving meibum quality in patients with meibomian gland dysfunction.
3

OCS-02, an anti-TNFa drop in phase 2 trials, is designed to treat ocular inflammation and apoptosis related to dry eye disease.
4

Softacort, currently in phase 4 trials, is an anti-inflammatory that may relieve symptoms of meibomian gland dysfunction.
5

New treatments for dry eye disease are being developed to address specific underlying causes, enhancing personalized patient care.

Shane R. Kannarr

Specialties: Optometry

Bio: Shane R. Kannarr, OD, is an optometrist whose clinical writing includes work on multifocal contact lens fitting and comfort. He coauthored a Contact Lens Spectrum peer-reviewed study evaluating delefilcon A daily disposable multifocal contact lenses in symptomatic presbyopic patients, with attention to comfort, dryness, vision, and fitting success.

Contributions:

https://clspectrum.com/issues/2020/november/peer-reviewed-multifocal-lens-fit-and-comfort/

Christoper J. Jacquinot, OD

Specialties: Optometry

Bio: Christoper J. Jacquinot, OD, is an optometrist who has written for Optometric Management on emerging pharmaceutical treatments in the dry eye disease pipeline.

Ryan A. Cedeno

Specialties: Optometry

Bio: Ryan A. Cedeno, OD, is an optometrist whose published work in Optometric Management addresses emerging pharmaceutical treatments for dry eye disease. His writing has covered therapies in development for dry eye disease, including treatments targeting ocular inflammation, meibomian gland dysfunction, and related inflammatory pathways.

PentaVision

Optometric Management

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

5 Key Takeaways

1

2

3

4

5

Recommendations